Vidal Daniel 4

What Happened

• Vidal Daniel, a director of Expensify, reported multiple transactions in March 2026. On 2026-03-13 he purchased 72,413 shares at $0.82 per share (total $59,379) under the company's stock purchase/matching plan and was granted 20,925 matched shares (no cash price). He also reported exercise/conversion of derivative interests for 2,826 shares on 2026-03-15. Separately, he sold 6,158 shares on 2026-03-17 at $0.76 ($4,680) and 1,510 shares on 2026-03-24 at $0.84 ($1,268).
• Purchases/awards are typically seen as more informative than routine sell-to-cover transactions; the reported purchases here are modest in value ($59k) while the open-market sales were small tranches (~7.7k shares for ~$5.95k).

Key Details

• Transaction dates and prices:
  • 2026-03-13: Purchase 72,413 @ $0.82 = $59,379 (SPMP purchase; F1)
  • 2026-03-13: Award/Matched shares 20,925 @ $0.00 (F2)
  • 2026-03-15: Exercise/conversion of derivative(s) for 2,826 shares (M; reported at $0.00/$N/A)
  • 2026-03-17: Open-market sale 6,158 @ $0.76 = $4,680
  • 2026-03-24: Open-market sale 1,510 @ $0.84 = $1,268
• Shares owned after the transactions: not stated in the provided filing excerpt.
• Notable footnotes: purchases were under the Expensify 2021 Stock Purchase & Matching Plan (F1, F2); some sales reflect broker sales to cover taxes on matched shares/RSU vesting (see F4–F7); certain RSU/long-term share types may have conversion/transfer restrictions (LT50 rules, F10, F9); some shares may be deposited into the company Voting Trust while the reporting person retains investment/dispositive control (F11).
• Filing timeliness: Report filed 2026-06-11 for transactions in March 2026 (period of report 2026-03-13), indicating a delayed filing relative to the transaction dates.

Context

• The 3/15 derivative entries indicate exercises/conversions of derivative securities (e.g., vested RSUs or similar instruments); some related zero-dollar disposals likely reflect internal settlement or share-for-share transfers rather than open-market cash sales.
• The small open-market sales appear consistent with routine sell-to-cover tax-withholding activity described in footnotes rather than large-scale divestiture.
• As always, these filings are factual disclosures of trades and grants; they do not by themselves prove intent or signal about future company performance.